Navigation Links
Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study
Date:2/26/2009

te, argue for consideration of fenofibrate in the clinical management of patients with type 2 diabetes and marked atherogenic dyslipidemia.

Professor Richard O'Brien, a diabetes specialist and Clinical Dean of Medicine at the University of Melbourne, Austin and Northern Clinical Schools, added:

These findings on macrovascular disease build on earlier results of the FIELD trial showing clear benefits for patients with microvascular complications. Fenofibrate reduces the need for laser treatment in patients with diabetic disease in the small vessels of the eyes. It also reduces the risk of amputations resulting from disease in the small vessels of the limbs.

FIELD (5), a large international multicentre trial in which 9795 patients were followed up over 5 years, was coordinated at the NHMRC Clinical Trials Centre at the University of Sydney. Professor Anthony Keech, Professor of Medicine, Cardiology and Epidemiology and Deputy Director of the trials centre, is chair of the trial.

Notes for Editors

What is the FIELD study?

The FIELD trial was a randomised, double-blind, placebo-controlled study in 9795 patients with type 2 diabetes. The study evaluated whether treatment with fenofibrate (200 mg/day) for a median of 5 years could reduce macrovascular and microvascular complications of type 2 diabetes. Macrovascular study endpoints were major coronary events (primary) and total cardiovascular events (secondary). Microvascular endpoints were laser treatment for diabetic retinopathy, progression of albuminuria and non-traumatic lower-extremity amputation.

What were the key macrovascular findings in the FIELD study?

After a mean of 5 years treatment, fenofibrate was associated with a non-significant 11% reduction in the primary endpoint. However, there was a significant reduction in the secondary endpoint (reduction b
'/>"/>

SOURCE Solvay
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. February 2009 Mayo Clinic Womens HealthSource Highlights Diabetes and Heart Disease, Going Vegetarian and Tinnitus
2. MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
3. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
4. Epidemics of Both Type 1 Diabetes (Insulin Dependent) and Type 2 Diabetes (Obesity Related) Are Linked to Immunization
5. Overweight Siblings of Children With Type 2 Diabetes Likely to Have Abnormal Blood Sugar Levels
6. Patient Recruitment Begins in India for Phase 3 Diabetes Trial
7. Opportunities to Highlight Type 1 Diabetes in November
8. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
9. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
10. TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program
11. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... MOUNTAIN VIEW, Calif., July 31, 2014 IRIDEX Corporation ... the second quarter and six months ended June 28, 2014.  ... quarter of 2014, up 15% from $9.2 million in the ... the first quarter of 2014. Revenues for the first six ... million in the first six months of last year. ...
(Date:7/31/2014)... 31, 2014  Cepheid (NASDAQ: CPHD ) today ... conferences, and invited investors to participate via webcast. ... New York, NY Wednesday, August 13, 2014 at ... Conference, New York, NY Thursday, September ... Accessing Live Webcasts To access the live webcasts for these ...
(Date:7/31/2014)... 2014 Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... the development of its lead molecule, Anatabine Citrate, in ... selected Quotient Clinical, The Translational Pharmaceutics Company, based in ... run its early development programs. The Company ... the end of the third quarter with the Medicines ...
Breaking Medicine Technology:IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Cepheid to Webcast Upcoming Financial Presentations 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4
(Date:8/2/2014)... When the Black Hat conventioneers descend on Las Vegas ... can be always counted on, plenty of FUD will be ... doubt. The run-up has already made its share of ... on July 31st about how hackers could use a ... infect a system with malware, completely undetected, by leveraging the ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Cannabis use among ... teens aged 14 to 17 having used marijuana at least ... With their slogan “Say ‘No’ to Drugs, Say ‘Yes to ... reaching out to youth this summer with factual information about ... past six months, Hamburg “Say ‘No’ to Drugs, Say ‘Yes’ ...
(Date:8/1/2014)... a central role in regulating appetite and whole-body metabolism. ... brain,s control of food intake and body weight, but ... been unclear. A new study in the ... activity in a type of neuron known as pro-opiomelanocortin ... high-fat diet. Sabrina Diano and colleagues at Yale ...
(Date:8/1/2014)... Aug. 1, 2014 (HealthDay News) -- The U.S. Food ... a new drug, Jardiance, to help fight type 2 ... or added to existing treatment regimens to control blood ... Curtis Rosebraugh, director of the Office of Drug Evaluation ... Research, said in an agency statement. The FDA ...
(Date:8/1/2014)... Summer is here, and with it comes ... summer, and they can be a pain for dogs. Animal ... all their customers get rid of ticks and prevent them ... in the summer, which is why they are so active ... and woodland areas and carry a number of diseases, including ...
Breaking Medicine News(10 mins):Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 2Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 3Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 4Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 5Health News:Addressing a Serious Issue Affecting German Teens 2Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:Tis the Season for Tick Prevention 2
... University of New Hampshire finds that U.S. children are routinely ... previously recognized, with nearly half experiencing a physical assault in ... abuse and crime than do adults," said David Finkelhor, director ... study director. "If life were this dangerous for ordinary grown-ups, ...
... BANGKOK, Oct. 6 As thousands of experts around ... health and nutrition at the International Congress of Nutrition ... and Mars, Incorporated are acknowledging the important impact of ... Science - Flavanols and Sustainability," scientists will present evidence ...
... Los Angeles back surgeon, Dr. Rezaian of the California Orthopedic ... Spinal Stenosis . Open back surgery used to be ... pinching nerves, however, recent medical advances have given patients requiring ... of hope. Doctors have pioneered a new laser Spinal Stenosis ...
... ANGELES, Oct. 6 The Renaissance Laser and Vein Institute offers ... stretch marks and sagging skin like never before. Thanks to recent ... skin care lasers in the dermatological and cosmetic skin care world. ... is the Titan Procedure . The Titan laser ...
... Pelosi and the Democratic Women,s Working Group joined leaders from women,s ... discuss how women stand to gain the most ... face discrimination in both coverage and cost if health reform fails. ... , On Why Health Insurance Reform is Essential for ...
... D.D.S., who practices general dentistry in Flint, Mich., was inducted ... during a meeting of the ADA House of Delegates in ... presidency in October 2010 and will lead the more than ... Gist will be the ADA,s first African-American president. , Dr. ...
Cached Medicine News:Health News:New study finds high rates of childhood exposure to violence and abuse in US 2Health News:Cocoa Research Finds a Place in the Global Health Dialogue 2Health News:Cocoa Research Finds a Place in the Global Health Dialogue 3Health News:Cocoa Research Finds a Place in the Global Health Dialogue 4Health News:Cocoa Research Finds a Place in the Global Health Dialogue 5Health News:California Surgeon (laserbacksurgery.com) Pioneers Exciting Alternative to Traditional Spinal Stenosis Treatment 2Health News:Southern California Renaissance Laser and Vein Institute (laserandveinclinic.com) Offers Cutting Edge New Titan Procedure 2Health News:Pelosi: Health Insurance Reform Essential for Women 2Health News:Pelosi: Health Insurance Reform Essential for Women 3Health News:Pelosi: Health Insurance Reform Essential for Women 4Health News:Pelosi: Health Insurance Reform Essential for Women 5Health News:Michigan Dentist Chosen President-Elect of the American Dental Association 2
... Injection is supplied in an isotonic solution ... intravenous administration. Each milliliter contains 37 megabecquerels ... calibration time, made isotonic with 9 milligrams ... benzyl alcohol. The pH is adjusted to ...
... single-detector system offers general purpose ... for gurneys and wheelchairs. This ... versatile open gantry, caudal/cephalic detector ... for SPECT and whole body ...
Stainless steel lancet blade in stainless steel....
Sharp diamond shaped double blade in stainless steel....
Medicine Products: